[ad_1]
The interruption of clinical trials of the vaccine against covid-19 that develops the Oxford University It is not a setback and it is not the first time that this has happened, said the British Minister of Health on Wednesday, Matt Hancock.
AstraZeneca Pharmaceutical, which develops the vaccine together with the English university, released a statement on Tuesday to report the pause in clinical trials after a volunteer in the United Kingdom suffered an adverse reaction.
(In context: Due to possible adverse reaction, Oxford vaccine tests suspended)
This possible vaccine, considered one of the most advanced developed in the worldor, it was in the final stages of clinical trials before receiving authorization from regulatory agencies to proceed with immunizing the population.
In a statement to the SkyNews network, Hancock admitted that this interruption is “Obviously a challenge for this particular vaccine. This is not actually the first time this has happened to the Oxford vaccine and it is a normal process in clinical trials“.
The minister considered that the pause in the tests “is not necessarily” a setback, and “it depends on what (the researchers) find when they do the research“.” There was a pause earlier in the summer (boreal) and that was resolved without problems, “added the head of Health.
AstraZeneca has not provided information on the health status of the volunteer who has fallen ill, but the media highlighted this Wednesday that his recovery is expected.
The potential vaccine, which gave promising results in early trials, was undergoing clinical trials in the United Kingdom, the United States, Brazil and South Africa.
(Read also: Argentina and Mexico will produce the Oxford vaccine for Latin America)
Last month, the Governments of Argentina and Mexico, as well as the Mexican Slim Foundation, reached an agreement with AstraZeneca and the University of Oxford to manufacture the vaccine for their countries and then distribute it to the rest of Latin America, except Brazil.
The president of Argentina, Alberto Fernández, reported in August that the objective was to develop between 150 and 250 million doses that would be available at affordable prices, with an individual cost between 3 and 4 dollars.
Read also
– Why authorities in China say they ‘defeated’ coronavirus outbreak
– What is needed for the Covid-19 vaccine to reach the country?
EFE
